Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single versus Dual Antiplatelet Therapy after CABG with Incomplete Revascularization
2017-001754-33Phase 3Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronary arteriosclerosis and Coronary artery bypass graft (CABG) comparing Single antiplatelet therapy (aspirin) with Dual antiplatelet therapy (aspirin + ticagrelor) (2 arms). Primary endpoint: cardiac mortality. Started Sep 2021; status: completed.
02
Drugs
aspirinticagrelor
03
Conditions
coronary arteriosclerosisCoronary artery bypass graft (CABG)
Beyond the preview
Go deeper on 2017-001754-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001754-33.